lundi 5 décembre 2016

Onco Actu du 5 décembre 2016

2.10 Etiologie - Alcool

Melanoma and Alcohol: Another Explanation [ACS]

5.12 Immunothérapies

Immune System, Unleashed by Cancer Therapies, Can Attack Organs [NY Times]

5.12.2 Immunothérapies - CAR-T

The Xconomy Immuno-Oncology Resource: A Mid-ASH T Cell Update [Xconomy]

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out [The Street]

Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission [EndPoints]

Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) [Business Wire]

5.12.3 Immunothérapies-combinaisons

Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study [BMS]

5.2 Pharma

Boehringer axes small-molecule discovery ops as R&D focus shifts to immuno-oncology [FierceBiotech]

5.4 Traitements - Economie

James Raftery: Changes to how NICE appraises drugs and other health technologies [BMJ]

5.8 ASH

As the world’s top blood experts gather, 5 key questions to watch

5.8.1 ASH - Communiqués

IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy [AbbVie]

Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma [Takeda]

Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma [AbbVie]

Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan [Roche]

Studies Advance a More Personalized Approach to Treatment [ASH]

Bioengineering Innovations Show Promise for Improving Treatments and Drug Delivery [ASH]

5.8.3 ASH - Divers

When yesterday’s cancer “discovery” is reversed by today’s better evidence — a cautionary tale for PR professionals and journalists [HealthNewsReview]

5.8.4 ASH - CAR T

Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL [Juno]

Rivals Kite and Novartis post new CAR-T data as both plot FDA approval [FierceBiotech]

CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL [Fred Hutch]

Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia [Kite]

Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL [Novartis]

In wake of a CAR-T restructuring, Novartis says it’s ready to hunt a pioneering OK for lead program [EndPoints]

Lethally severe neurotoxicity continues to haunt Juno’s CAR-T pipeline [EndPoints]

Novartis says 82 percent of leukemia patients in remission after CAR-T [Reuters]

New data on risk vs benefit for potent CAR-T cancer drugs [Reuters]

5.8.6 ASH - Leucémies

#ASH16: Pfizer offers a thumbs-up on OS data from PhII blood cancer study of glasdegib [EndPoints]

6.10.1 Politiques (USA)

Statement from the American Association for Cancer Research on the House Passage of the 21st Century Cures Act [AACR]

6.4 Médico-éco

Medicare recipients with cancer face financial distress [Reuters]

6.6 Publications

It’s time to overhaul the secretive peer review process [STAT]